SS Innovations revealed the appointment of Milan Rao as the company’s new chief operating officer (COO) and chief financial officer (CFO).

The global COO position is a newly created role at the company. Rao will succeed Naveen Kuman Amar as CFO following his resignation from SS Innovations for personal reasons. He will be based in the U.S. and work with the chairman executive leadership team during a planned transition period.

Rao boasts over three decades of executive leadership experience driving tech-enabled transformation, operational efficiency, and growth at global companies across industries, including the healthcare sector.

“Milan brings to SS Innovations a commendable track record of building high-performance teams and growing multinational businesses through his hands-on leadership approach,” said SS Innovations chairman and CEO Dr. Sudhir Srivastava. “His appointment reflects our commitment to attracting top talent to our executive team as we continue to expand the global footprint of our advanced, cost-effective SSi Mantra surgical robotic system. Milan will play an integral role in defining our growth strategy and delivering on our promise of democratizing robotic surgery for a broader segment of patients in need.”

Most recently, he’s been serving as COO and chief revenue officer of Markets and Markets, a global research and consulting firm. Before that, he had senior leadership roles including president and global business head of Smart Energy Water, a cloud-based SaaS company; president of Wipro Limited, a leading global technology services firm; and president & CEO for India & Emerging markets at GE Healthcare.

Earlier in his career, Rao gained financial and capital markets experience through leadership roles at Morgan Stanlet and Citibank.

“I am pleased to begin working with Dr. Srivastava and the SS Innovations leadership team during this transition,” said Rao. “SS Innovations has built a compelling and differentiated robotics platform and I look forward to contributing to the Company’s strategic direction, operational readiness and long-term value creation as the organization continues to evolve and scale.”

Earlier this week, the company announced that it has completed development of five new five-millimeter surgical instruments for use in pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures. SS Innovations also submitted its SSi Mantra surgical robot to the U.S. Food and Drug Administration (FDA) for 510(k) clearance last month.